Respiratory Disorders Treatment Market Size & Share, by Disease Type (Asthma, Chronic Obstructive Pulmonary Diseases (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis); Drug Class (Corticosteroids, Bronchodilators, Antibiotics, Mucolytic Agents); Route of Administration (Parenteral, Oral, Inhalational) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 1121
  • Published Date: Oct 07, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Respiratory Disorders Treatment Market size was valued at USD 108.37 billion in 2023 and is expected to reach USD 236.88 billion by 2036, registering around 6.2% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of respiratory disorders treatment is evaluated at USD 113.75 billion.

The primary factor for the growth of the market can be attributed to the increasing cases of respiratory disease worldwide. According to NCD alliance, 235 million people suffer from asthma worldwide. To cope with the large pool of patients companies are continuously working on innovating drugs to prevent or cure these diseases.


Get more information on this report: Request Free Sample PDF

Respiratory Disorders Treatment Sector: Growth Drivers and Challenges

Growth Drivers

Increasing Cases of COVID-19 to Increase Demand for Respiratory Disease Drugs

Since the starting of 2020, we have witnessed an exponential growth in the number of cases of COVID-19 worldwide. In majority of the cases, patients show symptoms similar to that of respiratory diseases. Thereby, it has increased the demand for respiratory drugs. Increased demand coupled with the necessity of developing a vaccine with drive the respiratory disorders treatment market in upcoming few years.

Increasing Level of Air Pollution to Increase Cases for Respiratory Diseases

Most of the developing countries where rapid industrialization is happening, are witnessing an increase in the level of air pollution which is one of the primary risk factor for respiratory disorders treatment such as COPD and asthma. As per the Global Asthma report, 2018, more than 1 billion people are affected by pulmonary diseases. High level of pollution contributes to the increasing number of respiratory disease patients which can further lead to growth of respiratory disorders treatment market.

Challenges

Lack of Testing Infrastructure to Diagnose Respiratory Disorders Treatment to Hamper Growth

Most of the developing nations do not have good healthcare facilities and they lack in infrastructure and COVID-19 has clearly exposed this limitation. Treatment of any disease starts only when the disease is diagnosed but the lack of testing infrastructure makes it extremely difficult to diagnose diseases among countries with high population. This limitation may hamper the market growth for respiratory diseases.

Side Effects of Drugs to Hamper Growth

Most of the respiratory disease drugs have side effects and hence people hesitate in using these drugs. So there is a challenge in-front of drug manufacturing companies to innovate and prepare drug which have either no side effects or they have only a few non-severe side effects.

Respiratory Disorders Treatment Market: Key Insights

Base Year

2023

Forecast Year

2024–2036

CAGR

6.2%

Base Year Market Size (2023)

USD 108.37 billion

Forecast Year Market Size (2036)

USD 236.88 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Respiratory Disorders Treatment Segmentation

The respiratory disorders treatment market is further segmented by disease type, drug class, route of administration, distribution channel and region. Disease type segment is further segmented into asthma, COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and Others. The increasing pool of patients of Asthma coupled with its high prevalence is expected to drive the market. Moreover, the popularity of inhalational type of drugs is rising on the back of its fast action and quick relief comparing to the conventional dosage forms. Thereby, the growth in these segments is expected to drive the respiratory disorders treatment market as well.

The high prevalence of diseases such as Asthma and COPD has increased the demand for drugs in hospitals and diagnostic centres. Moreover, with the increasing popularity of online pharmacies the supply chain in the field of drug delivery is expected to improve tremendously. On the back of these factors the respiratory disorders treatment market is expected to grow notably over the forecast period. 

Our in-depth analysis of the global market includes the following segments:

          By Disease Type

  • Asthma
  • COPD (Chronic Obstructive Pulmonary Disease)
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Cystic Fibrosis
  • Others

          By Drug Type

  • Corticosteroids
  • Bronchodilators
  • Monoclonal Antibodies
  • Antibiotics
  • Mucolytic Agents
  • Leukotriene Modifiers
  • Others

          By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail-Order Pharmacies

          By Route of Administration

  • Parenteral
  • Oral
  • Inhalational

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Respiratory Disorders Treatment Industry - Regional Synopsis

On the basis of regional analysis, the respiratory disorders treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

Currently, North America region holds the maximum market share on the back of increased awareness among the people about the respiratory diseases and the supporting government policies. The market is anticipated to grow significantly in Asia Pacific region during the forecast period owing to the increasing pool of the patients suffering from the disease and the rise in the air pollutants in the atmosphere.

Get more information on this report: Request Free Sample PDF

Companies Dominating the Respiratory Disorders Treatment Landscape

    • Mylan N.V.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Teva PharmaceuticalIndustries Ltd.
    • Sunovion Pharmaceuticals Inc.
    • Merck & Co., Inc.
    • BoehringerIngelheim Pharmaceuticals, Inc.
    • AstraZeneca Plc.
    • GlaxoSmithKline Plc.
    • Regeneron Pharmaceuticals, Inc.
    • Grifols, S.A.
    • Pfizer Inc.

In the News

  • March 2020 - Mylan re-started production of generic hydroxychloroquine sulfate tablets (200mg) to meet increasing demand in the context of COVID-19. Company doanated 10 million tablets to US Department of Health and Human Services.

Author Credits:  Radhika Pawar


  • Report ID: 1121
  • Published Date: Oct 07, 2024
  • Report Format: PDF, PPT
Chronic Respiratory Diseases Treatment Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample